These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33064934)

  • 1. Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.
    McMahan ZH; Tucker AE; Perin J; Volkmann ER; Kulkarni S; Ziessman HA; Pasricha PJ; Wigley FM
    Arthritis Care Res (Hoboken); 2022 Mar; 74(3):442-450. PubMed ID: 33064934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis.
    Abignano G; Mennillo GA; Lettieri G; Karadag DT; Carriero A; Padula AA; Del Galdo F; Khanna D; D'Angelo S
    J Rheumatol; 2021 Sep; 48(9):1422-1426. PubMed ID: 33452163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroparesis in systemic sclerosis: a detailed analysis using whole-gut scintigraphy.
    Adler B; Hummers LK; Pasricha PJ; McMahan ZH
    Rheumatology (Oxford); 2022 Nov; 61(11):4503-4508. PubMed ID: 35136977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
    Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
    Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
    Suliman YA; Kafaja S; Alemam M; Shaweesh Y; Tavakoli K; Furst DE
    J Scleroderma Relat Disord; 2021 Oct; 6(3):236-241. PubMed ID: 35387210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis.
    Hisada S; Takeuchi S; Tozawa T; Yamada Y; Ito Y; Kodera M
    J Dermatol; 2024 Oct; 51(10):1329-1334. PubMed ID: 38963343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
    Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C
    Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.
    Pellicano C; Oliva A; Colalillo A; Gigante A; D'Aliesio E; Al Ismail D; Miele MC; Cianci R; Mastroianni CM; Rosato E
    Clin Exp Med; 2024 Sep; 24(1):225. PubMed ID: 39294494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.
    Bodukam V; Hays RD; Maranian P; Furst DE; Seibold JR; Impens A; Mayes MD; Clements PJ; Khanna D
    Rheumatology (Oxford); 2011 Feb; 50(2):330-4. PubMed ID: 20884655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium.
    McMahan ZH; Frech T; Berrocal V; Lim D; Bruni C; Matucci-Cerinic M; Smith V; Melsens K; Proudman S; Zhang J; Mendoza F; Woods M; Khanna D
    J Rheumatol; 2019 Jan; 46(1):78-84. PubMed ID: 30442827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antivinculin Antibodies in Systemic Sclerosis: Associations With Slow Gastric Transit and Extraintestinal Clinical Phenotype.
    Herrán M; Adler BL; Perin J; Morales W; Pimentel M; McMahan ZH
    Arthritis Care Res (Hoboken); 2023 Oct; 75(10):2166-2173. PubMed ID: 36951252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome.
    Nguyen AD; Andréasson K; McMahan ZH; Bukiri H; Howlett N; Lagishetty V; Lee SM; Jacobs JP; Volkmann ER
    Semin Arthritis Rheum; 2023 Jun; 60():152185. PubMed ID: 36870237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
    Nagaraja V; Hays RD; Khanna PP; Spiegel BM; Chang L; Melmed GY; Bolus R; Khanna D
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1725-30. PubMed ID: 24692332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?
    Stamm L; Garaiman A; Becker MO; Bruni C; Dobrota R; Elhai M; Ismail S; Jordan S; Zampatti N; Tatu AM; Distler O; Mihai C
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
    Lee TH; Lee JS; Park S; Lee KA; Kim HS
    Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial.
    Marighela TF; Arismendi MI; Marvulle V; Brunialti MKC; Salomão R; Kayser C
    Rheumatology (Oxford); 2019 Nov; 58(11):1985-1990. PubMed ID: 31056685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
    Baron M; Hudson M; Steele R; Lo E;
    J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
    Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
    Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Associations Among Dysautonomia, Gastrointestinal Transit, and Clinical Phenotype in Patients With Systemic Sclerosis.
    Alvarez-Hernandez MP; Adler B; Perin J; Hughes M; McMahan ZH
    Arthritis Care Res (Hoboken); 2024 Dec; 76(12):1675-1685. PubMed ID: 39138019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.